Tx delay raises risk in patients with high-risk PCa

San Francisco--A 3-month delay in definitive treatment of high-risk prostate cancer patients seems to increase the risk of recurrence, according to Judd W. Moul, MD, director of the Center for Prostate Disease Research and professor of surgery,

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.